Matteo G. Doye

Advancing Medical and Biotech Solutions

from Scientific Insight to Real-World Impact

Scroll to Explore

A Personal Overview

I work across biotechnology, medical innovation, and applied scientific research. Over time, this has led me to build and operate several projects and companies that may appear unrelated on the surface: drug discovery, medical devices, and animal health products. In practice, they reflect a consistent approach: identifying unmet needs, applying scientific rigor, and turning ideas into tangible outcomes.

This website is designed to provide clarity for investors, partners, and potential acquirers about what I do, what I am focused on, and how to engage.

Current Focus

Ordered by current priority and time commitment

Primary

Wearable Emergency Medical Device

Portable, wearable emergency intervention device designed to improve outcomes in time-critical situations. Development is progressing with provisional patent protection in place.

Public details are intentionally limited. Technical documentation available under NDA for qualified parties.

High Priority

Alzheimer's Disease Drug Development

Development of an Asparagine Endopeptidase (AEP) inhibitor for Alzheimer's disease. Currently in lead optimization stage with mechanistic and translational work supporting clinical development pathway.

Operational

Dog Food Supplements

Animal health and nutrition business, maintained with limited day-to-day involvement. Established operational framework supports ongoing activities.

Research, Analysis, and Track Record

Biotech Clinical Trial Forecasting

I have published analytical papers focused on forecasting clinical trial outcomes and regulatory decisions for publicly traded biotechnology companies. These analyses were published prior to relevant events and used to inform structured strategies.

100% Directional Accuracy
~400% Cumulative Returns

Reported summary across published analyses with methodology available for review.

Published Research Papers

October 19, 2024 Confirmed

Simufilam as a Savior or a Simple Illusion? A Detailed Analysis of SAVA and its Lead Drug Candidate

A comprehensive analysis of Cassava Sciences and Simufilam, examining the scientific foundation and clinical trial structure. The assessment assigned a probability of success between 0.00032% to 0.0034%, indicating a high statistical likelihood of failure.

Outcome: Stock declined >85% upon data release on November 29, 2024
Read Paper →
January 13, 2025 Confirmed

MIST: A Great Long Play on The Way

Analysis estimating $5.21 price per share excluding current cash for Milestone Pharmaceuticals if Etripamil received FDA acceptance, with an estimated 80% probability of approval.

Outcome: Drug approved by FDA, yielding 250% positive return from CRL to approval
Read Paper →
April 27, 2025 Confirmed

Milestone Pharmaceuticals (MIST): Post-FDA Catalyst Update and How This Was a Golden Opportunity

Follow-up analysis after MIST received a Complete Response Letter for CMC issues. The CRL addressed chemistry, manufacturing, and control concerns—not safety or efficacy—presenting a favorable risk-to-reward opportunity at approximately $0.80 per share.

Outcome: Etripamil approved, position yielded 250% return
Read Paper →
July 31, 2025 Confirmed

Not So Fast Cowboy: A Detailed Analysis of ATYR and Efzofitimod

Critical analysis of aTyr Pharma's Phase III study for efzofitimod in pulmonary sarcoidosis. Preclinical studies showed no statistically significant impact on granuloma formation. The analysis estimated 65% probability of Phase III failure with projected 72% stock decline upon failure.

Outcome: Stock declined >83% upon data release on September 15, 2025
Read Paper →

Alzheimer's Disease Research & Drug Development

Beyond investment analysis, I conduct primary research into disease mechanisms and therapeutic approaches. My work on Alzheimer's disease proposes a novel perspective centered on the C/EBPβ-AEP pathway.

March 6, 2025 Mechanistic Research

That's What You Call a Strike: A Detailed Analysis of Alzheimer's Disease

This paper presents a new perspective on Alzheimer's Disease, challenging mainstream hypotheses while leveraging existing research. The work proposes focusing on the C/EBPβ-AEP pathway, which could potentially improve both AD and PD pathologies. It suggests a combination therapy between a lead compound targeting this pathway and a ketogenic diet.

Read Paper →

Following this research direction, I have pursued drugs and therapies with mechanisms of action similar to AEP inhibitors. This work was presented at the 25th Annual Biotech in Europe Forum in Basel in 2025, where partnership opportunities were explored.

Watch Presentation at Biotech in Europe Forum 2025

Agenda & Availability

March 9-11, 2026
BioCentury–BayHelix East-West Biopharma Summit
Seoul, South Korea
March 25 - April 3, 2026
United States Travel
Texas-based (including California, New York, and Salt Lake City)

Let's Connect

For investment or acquisition discussions, strategic partnerships, or scientific collaboration, please reach out using the form below or through any of the channels listed.

Confidential materials can be shared under NDA.

Thank you for your message. I will review your inquiry and respond as soon as possible.